文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

纳米颗粒载药对抗癌药物药代动力学的影响。

The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.

作者信息

Petschauer Jennifer S, Madden Andrew J, Kirschbrown Whitney P, Song Gina, Zamboni William C

机构信息

Division of Pharmacotherapy & Experimental Therapeutics, University of North Carolina at Chapel Hill (UNC) Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.

出版信息

Nanomedicine (Lond). 2015 Feb;10(3):447-63. doi: 10.2217/nnm.14.179.

DOI:10.2217/nnm.14.179
PMID:25707978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4594874/
Abstract

Major advances in carrier-mediated agents, which include nanoparticles, nanosomes and conjugates, have revolutionized drug delivery capabilities over the past decade. While providing numerous advantages, such as greater solubility, duration of exposure and delivery to the site of action over their small-molecule counterparts, there is substantial variability in systemic clearance and distribution, tumor delivery and pharmacologic effects (efficacy and toxicity) of these agents. This review provides an overview of factors that affect the pharmacokinetics and pharmacodynamics of carrier-mediated agents in preclinical models and patients.

摘要

在过去十年中，包括纳米颗粒、纳米脂质体和偶联物在内的载体介导药物取得了重大进展，彻底改变了药物递送能力。虽然这些药物具有诸多优势，比如相较于小分子药物具有更高的溶解度、更长的暴露时间以及能将药物递送至作用部位，但这些药物在全身清除率和分布、肿瘤递送以及药理作用（疗效和毒性）方面存在很大差异。本综述概述了在临床前模型和患者中影响载体介导药物药代动力学和药效学的因素。

相似文献

[1]
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.

Nanomedicine (Lond). 2015-2

[2]
Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.

Expert Opin Drug Metab Toxicol. 2015

[3]
Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.

Methods Mol Biol. 2018

[4]
Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.

Nanomedicine (Lond). 2017-7-26

[5]
Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.

Clin Pharmacol Ther. 2012-5

[6]
Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer.

Nanomedicine (Lond). 2017-9-27

[7]
Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Cancer Chemother Pharmacol. 2010-7-27

[8]
Bankruptcy filing worries developers of nanoparticle cancer drugs.

Nature. 2016-5-19

[9]
Concept and clinical evaluation of carrier-mediated anticancer agents.

Oncologist. 2008-3

[10]
Nanoparticles generated by PEG-Chrysin conjugates for efficient anticancer drug delivery.

Eur J Pharm Biopharm. 2014-8

引用本文的文献

[1]
Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1.

ACS Appl Mater Interfaces. 2025-1-8

[2]
Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer's Disease Management.

Pharmaceutics. 2023-12-29

[3]
Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer.

Int J Nanomedicine. 2023

[4]
Genetically engineered cellular nanoparticles for biomedical applications.

Biomaterials. 2023-5

[5]
Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy.

Pharmaceutics. 2022-6-27

[6]
DNA-Liposome Hybrid Carriers for Triggered Cargo Release.

ACS Appl Bio Mater. 2022-8-15

[7]
Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.

Int J Mol Sci. 2022-5-16

[8]
Immune response effects of diverse vaccine antigen attachment ways based on the self-made nanoemulsion adjuvant in systemic MRSA infection.

RSC Adv. 2018-3-14

[9]
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.

Adv Drug Deliv Rev. 2022-3

[10]
Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model.

Ther Adv Med Oncol. 2021-10-29

本文引用的文献

[1]
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old.

Cancer Chemother Pharmacol. 2014-1-18

[2]
Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).

PLoS One. 2014-1-8

[3]
Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma.

Sci Transl Med. 2013-10-30

[4]
Combining two strategies to improve perfusion and drug delivery in solid tumors.

Proc Natl Acad Sci U S A. 2013-10-28

[5]
Strategies for advancing cancer nanomedicine.

Nat Mater. 2013-11

[6]
Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.

J Pharmacol Exp Ther. 2013-9-16

[7]
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy.

Biomaterials. 2013-7-27

[8]
Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.

Nanomedicine. 2013-7-24

[9]
Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.

PLoS One. 2013-5-1

[10]
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

Cancer Res. 2013-2-19

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索